<DOC>
	<DOCNO>NCT01823718</DOCNO>
	<brief_summary>Patients patient enrol study Lymphoma cause EBV ( bone marrow transplantation , organ transplantation patient immunodeficient . They receive one three injection allogenic CTL specific EBV . The purpose study ensure injection cause GVH study side effect see whether therapy might help patient Lymphoma . Immunological monitoring also study .</brief_summary>
	<brief_title>Cell Bank Epstein Barr Virus Specific Cytotoxic T Lymphocytes</brief_title>
	<detailed_description />
	<criteria>Male female , without immunosuppressed organ transplant immunocompromised receive kidney transplant , kidneypancreas , heart lung heartlung , liver , cell hematopoietic stem cell , give consent Aged 18 75 year Children age 12 month , PS &lt; 4 Viral load determine EBV Life expectancy &gt; 1 month Patient type HLA DP DQ DR ABC Patients lymphoma immunosuppressed associate EBV failure , partial response ( &lt; 50 % ) relapse treatment monoclonal antibody / chemotherapy complete least three week . Patients partial response may PET scan confirm lack response . Patient measurable mass ass response bone marrow infiltration / measurable blood frozen tumor material repeat biopsy . Availability CTL match least two HLA one HLA validation expert tumor cell test de cytotoxicity negative Patient Pregnant lactate Concurrent infection HIV EBV negative lymphoma If acute GVHD &gt; grade II J1 injection ( case graft CSH ) Treatment molecule premarketing authorization old 21 day No match least two CTL HLA non expert validation use CTL HLA share single tumor Test cytotoxicity positive Lack recognition tumor cell available</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>